# EDGAR Filing Document

**Accession Number:** 0001903793
**File Stem:** 0001999371-26-009036
**Filing Date:** 2026-4
**Character Count:** 19269
**Document Hash:** 2feeee28f4eb4d5fe633f72c1577c41d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-26-009036.hdr.sgml**: 20260424

**ACCESSION NUMBER**: 0001999371-26-009036

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260424

**DATE AS OF CHANGE**: 20260424

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACHIEVE LIFE SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000949858
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 954343413
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-45969
- **FILM NUMBER:** 26895559

**BUSINESS ADDRESS:**
- **STREET 1:** 22722 29TH DR. SE
- **STREET 2:** SUITE 100
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98021
- **BUSINESS PHONE:** 425-686-1500

**MAIL ADDRESS:**
- **STREET 1:** 22722 29TH DR. SE
- **STREET 2:** SUITE 100
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ONCOGENEX PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20080821

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SONUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19950825
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TPG GP A, LLC
- **CENTRAL INDEX KEY:** 0001903793

**ORGANIZATION NAME:**
- **EIN:** 872054646
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 301 COMMERCE STREET
- **STREET 2:** SUITE 3300
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76102
- **BUSINESS PHONE:** (817) 871-4000

**MAIL ADDRESS:**
- **STREET 1:** 301 COMMERCE STREET
- **STREET 2:** SUITE 3300
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76102

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**ACHIEVE LIFE SCIENCES, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Jennifer L. Chu**<br>TPG Inc.<br>301 Commerce Street, Suite 3300<br>Fort Worth TX 76102<br>(817) 871-4000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**TPG GP A, LLC** | Name of reporting person<br>**TPG GP A, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**13755160.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**13755160.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**13755160.00** | Aggregate amount beneficially owned by each reporting person<br>**13755160.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**12.6%** | Percent of class represented by amount in Row (11)<br>**12.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** The number of shares of Common Stock (as defined below) beneficially owned as set forth in response to Items 7 through 11 above includes (i) 6,877,580 shares of Common Stock and (ii) 6,877,580 shares of Common Stock issuable upon exercise of 6,877,580 Warrants (as defined below).

The percentage beneficial ownership set forth in response to Item 13 above assumes that there is a total of 109,535,637 shares of Common Stock outstanding, which is the sum of (i) the 53,239,988 shares of Common Stock outstanding as of March 24, 2026, as reported in the Annual Report on Form 10-K filed by the Issuer (as defined below) with the Securities and Exchange Commission (the "Commission") on March 24, 2026, (ii) the 49,418,069 shares of Common Stock issued at the Closing (as defined below) and (iii) the 6,877,580 shares of Common Stock issuable upon exercise of the 6,877,580 Warrants reported herein.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**James G. Coulter** | Name of reporting person<br>**James G. Coulter** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**13755160.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**13755160.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**13755160.00** | Aggregate amount beneficially owned by each reporting person<br>**13755160.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**12.6%** | Percent of class represented by amount in Row (11)<br>**12.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The number of shares of Common Stock beneficially owned as set forth in response to Items 7 through 11 above includes (i) 6,877,580 shares of Common Stock and (ii) 6,877,580 shares of Common Stock issuable upon exercise of 6,877,580 Warrants.

The percentage beneficial ownership set forth in response to Item 13 above assumes that there is a total of 109,535,637 shares of Common Stock outstanding, which is the sum of (i) the 53,239,988 shares of Common Stock outstanding as of March 24, 2026, as reported in the Annual Report on Form 10-K filed by the Issuer with the Commission on March 24, 2026, (ii) the 49,418,069 shares of Common Stock issued at the Closing and (iii) the 6,877,580 shares of Common Stock issuable upon exercise of the 6,877,580 Warrants reported herein.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jon Winkelried** | Name of reporting person<br>**Jon Winkelried** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**13755160.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**13755160.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**13755160.00** | Aggregate amount beneficially owned by each reporting person<br>**13755160.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**12.6%** | Percent of class represented by amount in Row (11)<br>**12.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The number of shares of Common Stock beneficially owned as set forth in response to Items 7 through 11 above includes (i) 6,877,580 shares of Common Stock and (ii) 6,877,580 shares of Common Stock issuable upon exercise of 6,877,580 Warrants.

The percentage beneficial ownership set forth in response to Item 13 above assumes that there is a total of 109,535,637 shares of Common Stock outstanding, which is the sum of (i) the 53,239,988 shares of Common Stock outstanding as of March 24, 2026, as reported in the Annual Report on Form 10-K filed by the Issuer with the Commission on March 24, 2026, (ii) the 49,418,069 shares of Common Stock issued at the Closing and (iii) the 6,877,580 shares of Common Stock issuable upon exercise of the 6,877,580 Warrants reported herein.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
ACHIEVE LIFE SCIENCES, INC.

**(c) Address of Issuer's Principal Executive Offices:**
22722 29TH DR. SE., Suite 100, Bothell, WA, 98021

This Schedule 13D (the "Schedule 13D") relates to the Common Stock, par value $0.001 per share (the "Common Stock"), of Achieve Life Sciences, Inc. (the "Issuer").

**Item 4. Purpose of Transaction**

The information set forth in or incorporated by reference in Items 2, 3, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4.

Securities Purchase Agreement

TPG Auriga entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Issuer, dated as of April 15, 2026, pursuant to which it agreed to purchase, and the Issuer agreed to sell and issue, 6,877,580 shares of Common Stock and 6,877,580 accompanying Warrants at a collective price of $3.635 per combination of share of Common Stock and accompany Warrant (the "Private Placement").  On April 17, 2026, the Private Placement closed (the "Closing").  The aggregate purchase price of $25,000,003.30 paid by TPG Auriga for the shares of Common Stock and accompanying Warrants was funded by equity contributions of the limited partners of TPG Auriga.

Pursuant to the Securities Purchase Agreement, on April 15, 2026, the Board of Directors of the Issuer appointed Lucian Iancovici, as designated by TPG Auriga, to serve as a director of the Issuer, effective April 17, 2026.  The Issuer has agreed to nominate Dr. Iancovici for re-election to the Board of Directors at the Issuer's 2026 annual meeting of stockholders and the 2027 annual meeting of stockholders, until such time as TPG Auriga beneficially owns less than 5% of the Issuer's outstanding Common Stock.

Registration Rights Agreement

In connection with the Private Placement, TPG Auriga entered into a Registration Rights Agreement (the "Registration Rights Agreement") with the Issuer, dated as of April 15, 2026, providing for the registration under the Securities Act of 1933, as amended, for resale of the shares of Common Stock issued at Closing and the shares of Common Stock issuable upon exercise of the Warrants.

Other than as described above, none of the Reporting Persons nor, to the best knowledge of each of the Reporting Persons, without independent verification, any of the TPG GP A Officers, currently has any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although the Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.  As a result of these activities, one or more of the Reporting Persons may suggest or take a position with respect to potential changes in the operations, management or capital structure of the Issuer as a means of enhancing shareholder value.  Such suggestions or positions may include one or more plans or proposals that relate to or would result in any of the actions required to be reported herein, including, without limitation, such matters as acquiring additional securities of the Issuer or disposing of securities of the Issuer(greek question mark) entering into an extraordinary corporate transaction such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries(greek question mark) selling or transferring a material amount of assets of the Issuer or any of its subsidiaries(greek question mark) changing the present board of directors or management of the Issuer, including changing the number or term of directors or filling any existing vacancies on the board of directors of the Issuer(greek question mark) materially changing the present capitalization or dividend policy of the Issuer(greek question mark) materially changing the Issuer's business or corporate structure(greek question mark) changing the Issuer's certificate of incorporation, bylaws or instruments corresponding thereto or taking other actions which may impede the acquisition of control of the Issuer by any person(greek question mark) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association(greek question mark) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Act of 1933, as amended(greek question mark) and taking any action similar to  any of those enumerated above.

Reference to and description of the Warrants, Securities Purchase Agreement and Registration Rights Agreement set forth above in this Item 4 do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Common Warrant, form of Securities Purchase Agreement and form of Registration Rights Agreement, which have been filed as Exhibits 2, 3 and 4 and are incorporated herein by this reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 is incorporated by reference in its entirety into this Item 5.

The following sentence assumes that there is a total of 109,535,637 shares of Common Stock outstanding, which is the sum of (i) the 53,239,988 shares of Common Stock outstanding as of March 24, 2026, as reported in the Annual Report on Form 10-K filed by the Issuer with the Commission on March 24, 2026, (ii) the 49,418,069 shares of Common Stock issued at the Closing and (iii) the 6,877,580 shares of Common Stock issuable upon exercise of the 6,877,580 Warrants reported herein..  Pursuant to Rule 13d-3 under the Act, the Reporting Persons may be deemed to beneficially own 13,755,160 shares of Common Stock, which constitutes approximately 12.6% of the outstanding shares of Common Stock.

**(b)**
See response to Item 5(a) above.

**(c)**
Except as set forth in this Item 5, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, without independent verification, any person named in Item 2 hereof, has effected any transaction in the shares of Common Stock during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Items 2, 3, 4 and 5 of this Schedule 13D is incorporated by reference in its entirety into this Item 6.

Except as described above, to the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise), including, but not limited to, the transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, among the persons named in Item 2 or between such persons and any other person, with respect to any securities of Issuer, including, but not limited to, any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** TPG GP A, LLC

**Signature:** /s/ Matthew White

**Name/Title:** Matthew White / Vice President

**Date:** 04/24/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** James G. Coulter

**Signature:** /s/ Gerald Neugebauer

**Name/Title:** Gerald Neugebauer, on behalf of James G. Coulter (1)

**Date:** 04/24/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jon Winkelried

**Signature:** /s/ Gerald Neugebauer

**Name/Title:** Gerald Neugebauer, on behalf of Jon Winkelried (2)

**Date:** 04/24/2026